

091830323

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78333 A3

(51) International Patent Classification⁷: A61K 38/22, 38/26, A61P 3/08 // (A61K 38/22, 31:425)

(74) Agent: MACIAK, Ronald, S.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(21) International Application Number: PCT/US00/15548

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 6 June 2000 (06.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/139,794 21 June 1999 (21.06.1999) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

Published:

— With international search report.

(88) Date of publication of the international search report:
12 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): YAKUBU-MADUS, Fatima, Emitsel [NG/US]; 9303 Timberline Drive, Indianapolis, IN 46256 (US). STRAMM, Lawrence, E. [US/US]; 9143 Hadway Drive, Indianapolis, IN 46256 (US). JOHNSON, William, T. [US/US]; 1367 Maynard Drive, Indianapolis, IN 46227 (US). VIGNATI, Louis [US/US]; 5617 North Meridian Street, Indianapolis, IN 46208 (US).

A3

WO 00/78333 A3

(54) Title: SYNERGETIC USE OF THIAZOLIDINEDIONES WITH GLUCAGON-LIKE PEPTIDE-1 AND AGONISTS THEREOF TO TREAT NON-INSULIN DEPENDANT DIABETES

(57) Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 00/15548

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K38/22 A61K38/26 A61P3/08 // (A61K38/22, 31:425)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, MEDLINE, BIOSIS, PAJ, WPI Data, CANCERLIT, AIDSLINE, LIFESCIENCES, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	REASNER, C. A., II: "Promising new approaches" DIABETES, OBES. METAB. (1999), 1(SUPPL. 1), S41-S48, XP000971954 page S41, paragraph 1 -page S42 page S43, column 1, paragraph 3 -column 2, paragraph 3 page S44, column 1, paragraph 2 -page S45, column 2, paragraph 1	1-14, 19-21
Y	WO 98 57636 A (SMITH STEPHEN ALISTAIR ;SMITHKLINE BEECHAM PLC (GB)) 23 December 1998 (1998-12-23) page 1, line 9 - line 37 page 3, line 28 - line 31 page 4, line 4 - line 6 page 5, line 6 - line 21	1-14, 19-21
	---	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 January 2001

Date of mailing of the international search report

18/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Noë, V

INTERNATIONAL SEARCH REPORT

Intern [REDACTED] Application No

PCT/US 00/15548

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 631 224 A (EFENDIC SUAD ET AL) 20 May 1997 (1997-05-20) cited in the application abstract	15-18,22
Y	column 2, line 65 -column 3, line 40 column 4, line 47 - line 63 column 5, line 16 - line 20 examples 1,2 ----	1-14, 19-21
X	EP 0 733 644 A (LILLY CO ELI) 25 September 1996 (1996-09-25) abstract page 6, line 3 - line 20 page 7, line 55 -page 8, line 4 page 8, line 16 - line 22 page 8, line 36 - line 41 ----	15-18,22
A	WO 99 03478 A (BUCKINGHAM ROBIN EDWIN ;SMITH STEPHEN ALISTAIR (GB); SMITHKLINE BE) 28 January 1999 (1999-01-28) the whole document ----	
P,X	WO 00 00195 A (ODAKA HIROYUKI ;YAMANE MASAHIRO (JP); TAKEDA CHEMICAL INDUSTRIES L) 6 January 2000 (2000-01-06) abstract page 3, line 16 - line 24 page 20, line 11 - line 15 page 21, line 1 - line 13 page 25, line 29 -page 26, line 27 page 27, line 27 -page 28, line 15 page 28, line 31 -page 29, line 13 page 30, line 2 - line 5 ----	1,2, 4-12,14, 19-21

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 and 4 relate to compounds defined by reference to a desirable characteristic or property, namely incretin hormone is any hormone that is released after meals and that potentiates insulin secretion (claim 1) and glp-1 analog is any product that is structurally or functionally related to glp-1 (claim 4).

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to compounds mentioned in the description on page 9, line 20-26, page 13, line 1-22 and in claims 2 and 3.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern: [REDACTED] Application No

PCT/US 00/15548

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9857636	A 23-12-1998	AU 8216398	A	04-01-1999
		BG 104059	A	31-10-2000
		BR 9810444	A	05-09-2000
		CN 1260715	T	19-07-2000
		EP 0999837	A	17-05-2000
		NO 996265	A	17-12-1999
US 5631224	A 20-05-1997	AT 187647	T	15-01-2000
		AU 3888893	A	21-10-1993
		CN 1088835	A	06-07-1994
		DE 69327309	D	20-01-2000
		DE 69327309	T	13-07-2000
		WO 9318786	A	30-09-1993
		EP 0631505	A	04-01-1995
		JP 7504670	T	25-05-1995
EP 0733644	A 25-09-1996	US 5705483	A	06-01-1998
		AU 708159	B	29-07-1999
		AU 2026895	A	03-10-1996
		BR 9503036	A	23-09-1997
		CA 2150080	A	22-09-1996
		CN 1131674	A	25-09-1996
		CZ 9501321	A	16-10-1996
		FI 952536	A	22-09-1996
		HU 74729	A	28-02-1997
		JP 8269097	A	15-10-1996
		NO 952034	A	23-09-1996
		NZ 272186	A	29-01-1997
		PL 308783	A	30-09-1996
		US 6133235	A	17-10-2000
		US 5977071	A	02-11-1999
		ZA 9504141	A	22-11-1996
WO 9903478	A 28-01-1999	AU 8449098	A	10-02-1999
		BR 9810292	A	19-09-2000
		CN 1263467	T	16-08-2000
		EP 1001784	A	24-05-2000
		NO 20000230	A	17-01-2000
		PL 338140	A	25-09-2000
WO 0000195	A 06-01-2000	AU 4291499	A	17-01-2000
		JP 2000080047	A	21-03-2000